Research programme: protein kinase inhibitors - TargeGen

Drug Profile

Research programme: protein kinase inhibitors - TargeGen

Alternative Names: TG-100948; TG-101095; TG-101209

Latest Information Update: 30 Aug 2011

Price : $50

At a glance

  • Originator TargeGen
  • Class Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors; Platelet-derived growth factor inhibitors; Proto oncogene protein c ret inhibitors; Src-Family kinase inhibitors; Vascular endothelial growth factor A inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Age-related macular degeneration; Choroidal neovascularisation; Diabetic macular oedema; Myeloproliferative disorders; Retinal vascular occlusion

Most Recent Events

  • 30 Aug 2011 No development reported - Preclinical for Retinal vascular occlusion in USA (Topical)
  • 30 Aug 2011 No development reported - Preclinical for Myeloproliferative disorders in USA (PO)
  • 30 Aug 2011 No development reported - Preclinical for Diabetic macular oedema in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top